Business Wire

AL-ADTRAN

25.3.2024 14:01:34 CET | Business Wire | Press release

Share
Adtran and Vertilas answer AI demands with industry-first ultra-low-power 100G PAM4 single-mode VCSEL technology

Adtran and Vertilas today announced the industry’s first 100Gbit/s PAM4 single-mode vertical-cavity surface-emitting laser (VCSEL) technology with capabilities up to 1.6Tbit/s. On display at this week’s OFC, it sets new standards for low power consumption in optical engines and modules, with up to 80% reduction in power on the transmit optics compared to conventional solutions. Tailored specifically for the rigorous demands of intra-data center operations and AI/ML workloads, Adtran’s latest offering achieves unprecedented efficiency, consuming less than 2pJ/bit, including the laser driver. This significantly undercuts current industry standards, including those cited by co-packaged optics. The advancement is set to extend the capabilities of Adtran’s MicroMux family of small-form-factor pluggable transceivers. A major step towards meeting the needs of the rapidly expanding generative AI application market, Adtran’s latest innovation addresses the growing demand for robust, high-capacity and environmentally friendly data processing solutions.

“As the importance of data volume and speed escalates, the demand for increased bandwidth and enhanced energy efficiency accelerates. Our introduction of the market’s first 100Gbit/s PAM4 single-mode VCSEL technology, scalable to 1.6Tbit/s, epitomizes our proactive approach to tackling these emerging requirements. By pushing the limits of speed and significantly reducing power consumption, we’re creating tomorrow’s benchmarks,” said Ross Saunders, GM of optical engines at Adtran. “Our new technology promises to significantly improve intra-data center connectivity and AI application efficiencies, merging high performance with long-term sustainability. As we prepare for the leap towards 800Gbit/s and 1.6Tbit/s applications, we’re enhancing the foundations of efficient, high-capacity data ecosystems worldwide.”

Building on the success of Adtran’s MicroMux family, the new VCSEL technology leverages a short-cavity single-mode design and is based on indium phosphide semiconductor material. This enables it to operate across both O-band and C-band wavelengths, delivering 100Gbit/s per channel. By stacking multiple single-mode lasers into arrays, this approach achieves throughput of 800Gbit/s and 1.6Tbit/s, ensuring superior performance with a significant reduction in power consumption and costs. This enhanced energy efficiency presents a major advantage for IP router and Ethernet switch faceplate density. What’s more, its versatility extends to supporting a wide array of applications from DR4/8/16 to various FR4 links within optical engines, all while maintaining power consumption below 200mW per lane.

“As applications such as generative AI proliferate and enterprises expand their AI clusters, the need for advanced optical interconnects capable of supporting Terabit connectivity has reached a critical juncture. Our 100Gbit/s PAM4 single-mode VCSEL technology meets this challenge head-on. It enables energy efficiency and the capacity for higher-density deployments while at the same time addressing manufacturing, testing and assembly costs,” commented Christoph Glingener, CTO of Adtran. “This technology supports throughput of up to 800Gbit/s and 1.6Tbit/s, significantly reducing operational expenses while enhancing network capabilities. Our approach underscores a commitment to delivering sustainable, high-capacity networking solutions that break through existing barriers, readying networks for the next wave of AI infrastructure development.”

Demos of Adtran’s new VCSEL technology are available at this week’s OFC on request.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240322173283/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the

Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release

Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release

New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye